Measurement of infliximab and anti-drug antibody levels in patients with inflammatory bowel disease
- In: D25 What’s new in industry & science? Part 2 on Thursday, 6 September 2018, 10:40 -10:50
- At: Glasgow (Scotland) (2018)
- Type: Presentation
- By: MASUI, Sho (Kyoto University Hospital, Japan)
- Co-author(s): Sho Masui: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
Atsushi Yonezawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
Yasuaki Ikemi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
Masaya Denda: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
Yuki Otani: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
Satoshi Imai: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
Makoto Hayakari: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
Noriko Iwamoto: Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kyoto, Japan
Takashi Shimada: Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kyoto, Japan
Minoru Matsuura: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Hiroshi Nakase: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Kazuo Matsubara: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan - Abstract:
Background
Infliximab (IFX) is a chimeric mouse/human monoclonal antibody. IFX binds to tumor necrosis factor alpha (TNFα), and then suppresses the inflammation caused by certain autoimmune disorders, such as inflammatory bowel disease (IBD). Due to its immunogenicity, anti-drug antibodies (ADAs) are often produced in patients. Formation of
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023